Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Roche Holding Ltd ADR

Healthcare US RHHBY

53.35USD
-1.3(2.38%)

Last update at 2026-03-10T19:59:00Z

Day Range

53.0254.36
LowHigh

52 Week Range

31.7740.48
LowHigh

Fundamentals

  • Previous Close 54.65
  • Market Cap228847.75M
  • Volume462113
  • P/E Ratio17.77
  • Dividend Yield3.60%
  • EBITDA23000.00M
  • Revenue TTM63142.00M
  • Revenue Per Share TTM9.88
  • Gross Profit TTM 47828.00M
  • Diluted EPS TTM2.00

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 16327.00M 17398.00M 17965.00M 16614.00M 14148.00M
Minority interest -1110.00000M -1005.00000M 3432.00M 3120.00M 2744.00M
Net income 12421.00M 13930.00M 14295.00M 13497.00M 10500.00M
Selling general administrative 12124.00M 13249.00M 12614.00M 15078.00M 15367.00M
Selling and marketing expenses - - - - -
Gross profit 44770.00M 43154.00M 42146.00M 43115.00M 39577.00M
Reconciled depreciation 3844.00M 4443.00M 4558.00M 4292.00M 3586.00M
Ebit 21187.00M 20187.00M 19697.00M 21033.00M 18919.00M
Ebitda 20861.00M 22260.00M 23076.00M 21697.00M 18478.00M
Depreciation and amortization - - - - -
Non operating income net other - - - 0.00000M 0.00000M
Operating income 17476.00M 18155.00M 18543.00M 17548.00M 14743.00M
Other operating expenses 192.00M 238.00M 265.00M 227.00M 197.00M
Interest expense 690.00M 419.00M 553.00M 791.00M 744.00M
Tax provision 2796.00M 2463.00M 2897.00M 2506.00M 3283.00M
Interest income 1040.00M 677.00M 16.00M 99.00M 30.00M
Net interest income -673.00000M -414.00000M -542.00000M -702.00000M -758.00000M
Extraordinary items - - - 0.00000M 35.00M
Non recurring - - - 0.00000M 0.00000M
Other items - - - 0.00000M 0.00000M
Income tax expense 2796.00M 2463.00M 2897.00M 2506.00M 3283.00M
Total revenue 63281.00M 62801.00M 58323.00M 61466.00M 56846.00M
Total operating expenses 45805.00M 44646.00M 39780.00M 43918.00M 42103.00M
Cost of revenue 18511.00M 19647.00M 16177.00M 18351.00M 17269.00M
Total other income expense net - - - -5507.37423M -5852.33758M
Discontinued operations - - - 0.00000M 0.00000M
Net income from continuing ops 13531.00M 14935.00M 15068.00M 14108.00M 10865.00M
Net income applicable to common shares 12421.00M 13930.00M 14295.00M 13497.00M 10500.00M
Preferred stock and other adjustments - - - 0.00000M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 88151.00M 92317.00M 86138.00M 83091.00M 78517.00M
Intangible assets 9685.00M 12117.00M 12017.00M 8358.00M 9346.00M
Earning assets - - - - -
Other current assets 574.00M 382.00M 553.00M 574.00M 414.00M
Total liab 60159.00M 63972.00M 46365.00M 47224.00M 48151.00M
Total stockholder equity 27992.00M 24489.00M 36341.00M 32747.00M 27622.00M
Deferred long term liab - - - 0.00000M 0.00000M
Other current liab 6440.00M 6231.00M 9574.00M 10682.00M 6557.00M
Common stock 107.00M 160.00M 160.00M 160.00M 160.00M
Capital stock 107.00M 160.00M 160.00M 160.00M 160.00M
Retained earnings 38937.00M 34161.00M 45571.00M 40524.00M 34935.00M
Other liab 6615.00M 8455.00M 9868.00M 9558.00M 9041.00M
Good will 10820.00M 10809.00M 9249.00M 12456.00M 8948.00M
Other assets 8651.00M 8283.00M 7384.00M 6734.00M 5559.00M
Cash 2841.00M 6850.00M 5727.00M 6075.00M 6681.00M
Cash and equivalents 2150.00M 1822.00M 1191.00M 1306.00M 2542.00M
Total current liabilities 27239.00M 38416.00M 25401.00M 24119.00M 23033.00M
Current deferred revenue - - - - -
Net debt 20360.00M 24348.00M 8489.00M 8288.00M 12089.00M
Short term debt 2191.00M 14618.00M 2189.00M 1694.00M 722.00M
Short long term debt 3960.00M 15122.00M 3996.00M 1695.00M 2693.00M
Short long term debt total - - - 0.00000M 0.00000M
Other stockholder equity -11052.00000M -9832.00000M -9390.00000M -7937.00000M -7473.00000M
Property plant equipment 24208.00M 24412.00M 23270.00M 23318.00M 21818.00M
Total current assets 33816.00M 35627.00M 32942.00M 31254.00M 32244.00M
Long term investments - - - 1056.86M 738.44M
Net tangible assets 7487.00M 1563.00M 15075.00M 11701.00M 9328.00M
Short term investments 4776.00M 6181.00M 6607.00M 5783.00M 6437.00M
Net receivables 13668.00M 12628.00M 11699.00M 11964.00M 11401.00M
Long term debt 21391.00M 16076.00M 10220.00M 12668.00M 16077.00M
Inventory 8605.00M 7715.00M 7194.00M 6055.00M 6621.00M
Accounts payable 4132.00M 4115.00M 3638.00M 3176.00M 3082.00M
Total permanent equity - - - 0.00000M 0.00000M
Noncontrolling interest in consolidated entity - - - 0.00000M 0.00000M
Temporary equity redeemable noncontrolling interests - - - 0.00000M 0.00000M
Accumulated other comprehensive income - - - 0.00000M 0.00000M
Additional paid in capital - - - 0.00000M 0.00000M
Common stock total equity - - - 0.00000M 0.00000M
Preferred stock total equity - - - 0.00000M 0.00000M
Retained earnings total equity - - - 0.00000M 0.00000M
Treasury stock - - - 0.00000M 0.00000M
Accumulated amortization - - - 0.00000M 0.00000M
Non currrent assets other 948.00M 834.00M 617.00M 451.00M 428.00M
Deferred long term asset charges - - - 0.00000M 0.00000M
Non current assets total 54335.00M 56690.00M 53196.00M 51837.00M 46273.00M
Capital lease obligations 1193.00M 1354.00M 1195.00M 1219.00M 0.00000M
Long term debt total 22282.00M 17101.00M 11096.00M 13547.00M 16077.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 1127.00M 363.00M -997.00000M 827.00M 826.00M
Change to liabilities 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total cashflows from investing activities -3536.00000M -6552.00000M -9067.00000M -8634.00000M -7195.00000M
Net borrowings -6103.00000M 16348.00M 290.00M -4775.00000M -122.00000M
Total cash from financing activities -16275.00000M -13108.00000M -9666.00000M -14173.00000M -10691.00000M
Change to operating activities -2418.00000M -994.00000M -2060.00000M 149.00M 176.00M
Net income 12421.00M 13930.00M 14295.00M 13497.00M 10500.00M
Change in cash -1859.00000M 1123.00M -348.00000M -606.00000M 1962.00M
Begin period cash flow 6850.00M 5727.00M 6075.00M 6681.00M 4719.00M
End period cash flow 4991.00M 6850.00M 5727.00M 6075.00M 6681.00M
Total cash from operating activities 18415.00M 20976.00M 18566.00M 22385.00M 19979.00M
Issuance of capital stock 1257.00M 1406.00M 2126.00M 947.00M 448.00M
Depreciation 3844.00M 4443.00M 4558.00M 4292.00M 3586.00M
Other cashflows from investing activities 51.00M -73.00000M -274.00000M 65.00M 128.00M
Dividends paid 7446.00M 7773.00M 7700.00M 7449.00M 7094.00M
Change to inventory - - - 0.00000M 0.00000M
Change to account receivables - - - 0.00000M 0.00000M
Sale purchase of stock 0.00000M -18991.00000M - 0.00000M 0.00000M
Other cashflows from financing activities -1469.00000M -1286.00000M -130.00000M -1028.00000M -3051.00000M
Change to netincome 4564.00M 3589.00M 1764.00M 4435.00M 5706.00M
Capital expenditures 3449.00M 3693.00M 3528.00M 3503.00M 4043.00M
Change receivables - - - 0.00000M 0.00000M
Cash flows other operating - - - 0.00000M 0.00000M
Exchange rate changes - - - 0.00000M 0.00000M
Cash and cash equivalents changes - - - 0.00000M 0.00000M
Change in working capital -8227.00000M -994.00000M -2060.00000M 149.00M 176.00M
Stock based compensation 738.00M 663.00M 713.00M 597.00M -
Other non cash items 1131.00M 722.00M 540.00M 901.00M 620.00M
Free cash flow 13863.00M 16427.00M 11876.00M 17489.00M 15057.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RHHBY
Roche Holding Ltd ADR		 -1.3 2.38% 53.35 17.77 11.90 3.67 7.26 4.15 13.04
LLY
Eli Lilly and Company		 -7.04 0.70% 1001.35 78.14 31.95 16.34 45.83 16.65 54.36
JNJ
Johnson & Johnson		 1.12 0.46% 243.71 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc		 -0.44 0.19% 227.01 61.52 14.86 5.62 51.62 6.76 20.58
MRK
Merck & Company Inc		 -0.02 0.02% 117.09 59.83 12.33 4.50 6.47 4.94 23.79

Reports Covered

Stock Research & News

View All

Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD); and strategic agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize zilebesiran. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

Roche Holding Ltd ADR

Konzern Hauptsitz, Basel, Switzerland, 4070

Key Executives

Name Title Year Born
Dr. Severin Schwan Ph.D. CEO & Exec. Director 1967
Dr. Alan Hippe Chief Financial & Information Officer 1967
Ms. Cristina A. Wilbur Chief People Officer 1967
Dr. Johannes Carolus Clevers M.D., Ph.D. Head of Roche Pharma Research & Early Devel. 1957
Dr. Thomas Schinecker Chief Exec. Officer of Roche Diagnostics 1975
Mr. William N. Anderson Chief Exec. Officer of Roche Pharmaceuticals 1966
Dr. Bruno Eschli Head of Investor Relations NA
Ms. Claudia Bockstiegel Gen. Counsel 1964
Ms. Pascale Schmidt Chief Compliance Officer 1973
Ms. Barbara Schadler Head of Group Communications 1962

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.